Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy - Archive ouverte HAL Access content directly
Journal Articles Transplant Infectious Disease Year : 2016

Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy

Abstract

Epstein-Barr virus (EBV) displays oncogenic properties, particularly in the immunocompromised host. Notably, hematopoietic stem cell transplantation (HSCT) recipients with a detectable blood EBV viral load (BEBVL) are considered at higher risk of post-transplant lymphoproliferative diseases (PTLD). Therefore, BEBVL is monitored after HSCT, and preemptive rituximab may be used in patients with high values. However, little is known about post-HSCT BEBVL dynamics, and the threshold that should lead to anti-CD20 therapy is poorly defined.

Dates and versions

hal-02059996 , version 1 (07-03-2019)

Identifiers

Cite

Mihaja Raberahona, Chloe Wackenheim, Raphaële Germi, Martin Carré, Claude-Eric Bulabois, et al.. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy. Transplant Infectious Disease, 2016, 18 (6), pp.889-895. ⟨10.1111/tid.12618⟩. ⟨hal-02059996⟩
730 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More